OakChart

Gelteq Ltd

GELSHealthcare·Drug Manufacturers - Specialty & Generic·Australia·Nano·NASD·Nov 11 • 4:00 PM ET

0.4207+0.0006 (0.14%)
2026-11-12 01:32 CET
Market cap
4.70 USD m
Revenue, TTM
0.11 USD m
Net income, TTM
-4.57 USD m
Free cash flow, TTM
-1.84 USD m
EPS diluted, TTM
-0.45
P/E
-
Compare

Price

GELS against its 20, 50 and 200-day averages
2050200
0.501.001.502.0076.7M153.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GELSclose 0.4220-day 0.4550-day 0.55200-day 0.630.4252w high

79.1% under the 52-week high of 2.01 on 11 Jun 2026. 52-week low 0.39 on 20 May 2026. Last 15 sessions, 28.9% high to low

Volume 0.01× normal · the line is the 50-bar volume average

Profile

GELS
52-week range, 2% of the way up
0.392.01

Gelteq Ltd. operates as a biotechnology company. It focuses on the development and commercialization of white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. The firm also offers edible gels. The company was founded by Nathan J. Givoni and Simon H. Szewach on October 15, 2018 and is headquartered in Melbourne, Australia.

IPOOct 29, 2024
Beta-0.28
ATR, 14d0.04
Rel volume0.01
Short float4.06%
Inst own1.13%

Snapshot

6 groups

Valuation

Index-
Market Cap4.51M
Enterprise Value-
Income-4.57M
Sales0.11M
Book/sh0.85
Cash/sh0.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOOct 29, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S40.97
P/B0.50
P/C450.64
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio-
Current Ratio0.09
Debt/Eq0.36
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.45
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-18.35% -
Sales past 3/5Y0.08% -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own-
Insider Trans-
Inst Own1.13%
Inst Trans5.96%
ROA-31.56%
ROE-43.32%
ROIC-48.23%
Gross Margin-869.36%
Oper. Margin-4107.16%
Profit Margin-4350.49%
SMA20-7.20%
SMA50-22.99%
SMA200-33.71%
Trades-

Technical

Shs Outstand9.44M
Shs Float5.62M
Short Float4.06%
Short Ratio0.08
Short Interest0.23M
52W High2.01 -79.07%
52W Low0.39 8.71%
Volatility7.84% 8.01%
ATR (14)0.04
RSI (14)36.84
Beta-0.28
Rel Volume0.01
Avg Volume2.81M
Volume31,737

Performance

Perf Week-8.76%
Perf Month-12.37%
Perf Quarter-27.59%
Perf Half Y-6.22%
Perf YTD-47.41%
Perf Year-61.05%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close0.42
Price0.42
Change %0.14%

Peers

Mkt cap
TickerCompanyMkt cap
AQSTAquestive Therapeutics Inc449.96M
LFCRLifecore Biomedical Inc242.60M
YCBDcbdMD Inc4.43M
ETONEton Pharmaceuticals Inc1.97B
RDHLRedhill Biopharma Ltd ADR3.25M
SNOASonoma Pharmaceuticals Inc5.94M
CPIXCumberland Pharmaceuticals Inc91.70M
SBFMSunshine Biopharma Inc2.09M
PAHCPhibro Animal Health Corp1.43B
LFVNLifevantage Corp59.86M

News

latest 14 of 74
  • Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs (GlobeNewswire) -7.32%
  • Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq Technology for Animal Health Applications (GlobeNewswire) -35.29%
  • Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion (GlobeNewswire) +5.78%
  • Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway (GlobeNewswire) +16.66%
  • Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA (ACCESSWIRE)
  • Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth (GlobeNewswire)
  • Healthy Extracts Reports Preliminary 2025 Results, Net Revenue Expected Up 45% to Record $4.5 Million (ACCESSWIRE) -8.04%
  • Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership (GlobeNewswire)
  • Gelteq announces preclinical results on medicinal cannabinoid absorption (TipRanks) +39.24%
  • Stock Market Today: Dow Jones, Nasdaq 100 Futures Tumble Ahead Of Supreme Court Ruling On Trump's Tariffs-Wells Fargo, BP, WeRide In Focus (Benzinga)
  • What's Driving Gelteq Ltd.'s (GELS) Over 69% After-Hours Surge? (Benzinga) +6.44%
  • Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform (GlobeNewswire)
  • Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program (GlobeNewswire)
  • Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq's Nutritional Product Expansion into China (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.259-0.25-0.246-0.429
Period2022202320242025
EPS, quarterly--0.094-
PeriodQ3 '22Q4 '22Q3 '23
Sales, annual0.1070.05400.107
Period2022202320242025
Sales, quarterly00.1050
PeriodQ3 '22Q4 '22Q3 '23
Shares, annual9.4389.4389.43810.028
Period2022202320242025
Shares, quarterly-9.438-
PeriodQ3 '22Q4 '22Q3 '23

Income statement, annual

Currency USD, millions
MetricTTM2024FY2023FY2022FY
Total Revenue0.11-0.000.050.11
Cost of Goods Sold Incl. D&A1.02-0.791.361.17
Gross Profit-0.91--0.79-1.31-1.07
Selling, General and Administrative Excl. Other3.40-1.010.951.05
Research and Development0.45-0.180.450.38
Other Operating Expense0.00-0.110.000.00
Operating Income-4.32--1.92-2.26-2.11
Interest Expense1.43-0.390.270.13
Unusual Expense-1.00-0.110.040.37
Net Income Before Taxes-4.77--2.42-2.54-2.61
Income Taxes-0.20--0.09-0.18-0.16
Consolidated Net Income-4.57--2.32-2.36-2.44
Net Income From Continuing Operations-4.57--2.32-2.36-2.44
Net Income-4.57--2.32-2.36-2.44
EPS (Recurring)-0.50--0.24-0.25-0.23
EPS (Basic, Before Extraordinaries)-0.45--0.25-0.25-0.26
EPS (Diluted)-0.45--0.25-0.25-0.26
EBITDA-3.52--1.12-1.44-1.23
Non-Operating Income (Expense)-0.02-0.000.040.00
Other After Tax Adjustments--0.000.000.00
Stock Option Compensation Expense---0.000.03
Price To Sales Ratio79.81----
Gross Margin-869.36---2,439.97-995.99
Operating Margin-4,107.16---4,213.75-1,975.14
Net Margin-4,350.49---4,391.37-2,283.43
Shares Outstanding11.18-9.449.449.44
Market Capitalization4.70-17.08--

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Total Revenue0.000.110.00
Cost of Goods Sold Incl. D&A0.410.610.40
Gross Profit-0.41-0.51-0.40
Selling, General and Administrative Excl. Other2.031.371.16
Research and Development0.250.200.21
Other Operating Expense0.000.000.00
Operating Income-2.44-1.88-1.56
Interest Expense0.590.840.41
Unusual Expense-0.46-0.540.42
Net Income Before Taxes-2.57-2.20-2.26
Income Taxes-0.12-0.08-0.08
Consolidated Net Income-2.45-2.12-2.18
Net Income From Continuing Operations-2.45-2.12-2.18
Net Income-2.45-2.12-2.18
EPS (Recurring)-0.26-0.25-0.14
EPS (Basic, Before Extraordinaries)-0.23-0.21-0.16
EPS (Diluted)-0.23-0.21-0.16
EBITDA-2.03-1.48-1.16
Non-Operating Income (Expense)-0.00-0.020.13
Price To Sales Ratio79.81165.10-
Gross Margin--482.13-
Operating Margin--1,784.88-
Net Margin--2,017.01-
Shares Outstanding11.1810.0313.85
Market Capitalization4.7016.3317.08

Balance sheet, annual

Currency USD, millions
Metric2024FY2023FY2022FY
Cash & Short Term Investments-0.020.270.11
Short Term Receivables-0.120.230.17
Inventories-0.000.120.12
Other Current Assets-0.060.050.09
Total Current Assets-0.200.660.50
Net Property, Plant & Equipment-0.010.010.03
Total Investments and Advances-0.000.000.00
Intangible Assets-13.6514.3115.57
Other Assets-0.000.000.00
Total Assets-13.8614.9716.10
Short Term Debt Incl. Current Port. of LT Debt-1.390.010.03
Accounts Payable-0.260.190.15
Other Current Liabilities-0.930.700.57
Total Current Liabilities-2.580.910.74
Long Term Debt-1.181.651.01
Provision for Risks Charges-0.010.000.00
Other Liabilities-0.000.000.00
Total Liabilities-3.772.551.76
Non-Equity Reserves-0.000.000.00
Preferred Stock - Carrying Value-0.000.000.00
Common Equity-10.0912.4214.34
Total Shareholders Equity-10.0912.4214.34
Accumulated Minority Interest-0.000.000.00
Total Equity-10.0912.4214.34
Total Liabilities & Stockholders Equity-13.8614.9716.10
Book Value Per Share-1.071.321.52
Tangible Book Value Per Share--0.38-0.20-0.13
Full-Time Employees-202020
Price to Book Ratio-1.69--
Return on Assets--16.12-15.18-
Return on Equity--20.65-17.63-
Return on Invested Capital--20.63-16.77-15.91
Quick Ratio-0.080.600.50
Current Ratio-0.080.730.67

Cash flow, annual

Currency USD, millions
MetricTTM2024FY2023FY2022FY
Net Income---2.32-2.36-2.44
Depreciation--0.790.830.88
Other Funds (Non Cash)--0.390.090.18
Funds from Operations-1.14--1.14-1.45-1.39
Extraordinary Item--0.000.000.00
Changes in Working Capital--0.440.260.29
Cash from Operating Activities-1.84--0.70-1.19-1.09
Capital Expenditures-0.24--0.10-0.050.00
Net Assets From Acquisitions--0.000.000.00
Sale of Fixed Assets and Businesses0.00-0.000.000.00
Purchase or Sale of Investments--0.000.000.00
Purchase of Investments--0.000.000.00
Sale Or Maturity of Investments--0.000.000.00
Other Uses--0.000.000.00
Other Sources0.01-0.000.000.00
Cash from Investing Activities-0.29--0.10-0.050.00
Cash Dividends Paid--0.000.000.00
Change in Capital Stock0.32-0.000.880.00
Repurchase of Common Pref Stock--0.000.000.00
Sale of Common Pref Stock0.32-0.000.880.00
Proceedsfrom Stock Options0.32-0.000.880.00
Issuance or Reduction of Debt, Net--0.560.511.08
Change in Long Term Debt--0.560.511.08
Issuance of Long Term Debt--0.560.511.08
Reduction of Long Term Debt--0.000.000.00
Net Financing Active Other Cash Flow--0.000.000.00
Other Financing Activities Uses--0.000.000.00
Cash from Financing Activities0.14-0.551.371.08
Exchange Rate Effect-0.10-0.000.040.00
Net Change in Cash-2.09--0.250.16-0.01
Free Cash Flow-1.84--0.70-1.21-1.09
Preferred Dividends (Cash Flow)--0.000.000.00
Deferred Taxes & Investment Tax Credit--0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Cash & Short Term Investments0.010.231.89
Short Term Receivables0.280.300.19
Inventories-0.000.00
Other Current Assets0.070.460.98
Total Current Assets0.360.993.06
Net Property, Plant & Equipment0.010.010.01
Total Investments and Advances-0.000.00
Intangible Assets12.8813.0112.48
Other Assets0.180.060.00
Total Assets13.4214.0715.55
Short Term Debt Incl. Current Port. of LT Debt3.402.752.40
Accounts Payable0.360.120.11
Other Current Liabilities0.150.821.37
Total Current Liabilities3.923.693.89
Long Term Debt0.010.010.01
Other Liabilities0.000.000.00
Total Liabilities3.953.723.91
Non-Equity Reserves-0.000.00
Preferred Stock - Carrying Value-0.000.00
Common Equity9.4710.3611.64
Total Shareholders Equity9.4710.3611.64
Accumulated Minority Interest-0.000.00
Total Equity9.4710.3611.64
Total Liabilities & Stockholders Equity13.4214.0715.55
Book Value Per Share0.851.030.84
Tangible Book Value Per Share-0.30-0.26-0.06
Price to Book Ratio0.501.431.69
Return on Assets-31.56--
Return on Equity-43.32--
Return on Invested Capital-25.87-20.45-18.76
Quick Ratio-0.270.79
Current Ratio0.090.270.79

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S1
Funds from Operations-0.71-0.44-2.38
Extraordinary Item-0.000.00
Cash from Operating Activities-0.71-1.13-2.38
Capital Expenditures-0.05-0.19-0.22
Net Assets From Acquisitions-0.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments-0.000.00
Purchase of Investments-0.000.00
Sale Or Maturity of Investments-0.000.00
Other Uses--0.060.00
Other Sources0.010.000.00
Cash from Investing Activities-0.04-0.25-0.22
Cash Dividends Paid-0.000.00
Preferred Dividends (Cash Flow)-0.000.00
Change in Capital Stock0.53-0.214.00
Repurchase of Common Pref Stock-0.000.00
Sale of Common Pref Stock0.53-0.214.00
Proceedsfrom Stock Options0.53-0.214.00
Issuance or Reduction of Debt, Net0.01-0.190.49
Change in Long Term Debt--0.190.49
Issuance of Long Term Debt-0.350.49
Reduction of Long Term Debt--0.540.00
Net Financing Active Other Cash Flow-0.000.00
Other Financing Activities Uses-0.000.00
Cash from Financing Activities0.54-0.404.49
Exchange Rate Effect-0.08-0.020.10
Net Change in Cash-0.29-1.792.00
Free Cash Flow-0.71-1.13-2.38

Revenue breakdown

Pharmaceutical Preparations2023: 53.72K
Australia2023: 53.72K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.06%0.2M5.6M2.81M
2026-10-155.60%0.3M5.6M2.82M
2026-09-309.27%0.5M5.6M2.86M
2026-09-153.89%0.2M5.6M2.42M
2026-08-310.28%0.0M5.6M3.56M
2026-08-140.23%0.0M5.6M3.63M
2026-07-310.60%0.0M5.6M3.67M
2026-07-152.00%0.1M5.6M3.70M
2026-06-302.98%0.2M5.6M3.64M
2026-06-157.59%0.4M5.6M3.51M
2026-05-291.37%0.1M5.6M74.07K
2026-05-152.15%0.1M5.6M67.73K
2026-04-300.66%0.0M5.6M19.28K
2026-04-151.01%0.1M5.6M47.08K
2026-03-311.28%0.1M5.6M1.01M
2026-03-131.78%0.1M5.6M1.01M
2026-02-272.42%0.1M5.6M1.01M
2026-02-132.58%0.1M5.6M1.98M
2026-01-302.31%0.1M5.6M1.98M
2026-01-1517.85%1.0M5.6M1.94M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-02NT 20-F2026-06-30SEC
2026-07-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-31SEC
2026-06-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-02SEC
2026-05-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-26SEC
2026-03-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-24SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2025-12-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-09SEC
2025-11-1720-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-06-30SEC
2025-11-03NT 20-F2025-06-30SEC
2025-08-29EFFECTEffectiveness filing by commission orderSEC
2025-08-29424B3SEC
2025-08-28CORRESPSEC
2025-07-25F-1/ASEC
2025-07-08UPLOADUpload SubmissionSEC
2025-07-01F-1Registration statement for certain foreign private issuersSEC
2025-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162024-12-31SEC
2025-03-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-03-14SEC
2024-11-1520-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2024-06-30SEC
2024-10-31NT 20-F2024-06-30SEC
2024-10-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162024-10-30SEC
2024-10-28CERTSEC
2024-10-22424B4SEC
2024-10-178-A12BSEC
2024-09-30EFFECTEffectiveness filing by commission orderSEC
2024-09-26CORRESPSEC
2024-09-26CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
TWO SIGMA SECURITIES, LLC0.30%
JANE STREET GROUP, LLC0.27%
WEDBUSH SECURITIES INC0.18%
Private Advisor Group, LLC0.15%
MORGAN STANLEY0.13%
CITADEL ADVISORS LLC0.10%
UBS Group AG0.00%

Funds

Fund% owned
VANGUARD TOTAL INTERNATIONAL BOND II INDEX FUND1,334%
VANGUARD TOTAL INTERNATIONAL BOND INDEX FUND827.81%
Thornburg Strategic Income Fund329.7%
Fidelity Series International Developed Markets Bond Index Fund308.48%
VANGUARD DEVELOPED MARKETS INDEX FUND192.03%
iShares Core MSCI EAFE ETF147.03%
Capital World Bond Fund102.98%
Fidelity SAI International Low Volatility Index Fund98.91%
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND93.56%
MFS International Growth Fund91.49%

OakChart. GELS. Cached 15 minutes.

Some panels did not load: ratings, insider.